Treatment and survival of DH lymphomas
| Study . | No. of DH/total study size (%) . | Treatment regimen* . | Overall response rate, n/N (%)† . | Median survival, y . |
|---|---|---|---|---|
| Bertrand et al40 2007 | 10/17 (59) | NA | 5/10‡ (50) | < 1§ |
| Johnson et al15 2009 | 54/54 (100) | RCHOP (11/54);HDC+/− SCT‖ (6/54); CHOP (23/54); P (14/54) | NA | HD, 0.26; RCHOP, 1.40; CHOP-like, 0.42; P 0.07 |
| Kanungo et al13 2006 | 14/14 (100) | CT-NOS (11); R¶ (1); CT and BMT (1); CT, BMT, and RT (1) | NA | < 1§ |
| Le Gouill et al10 2007 | 16/16 (100) | CEEP/COPADM + Auto-SCT/BEAM (1); CHOP/IVAM (1); COPADM/CYVE (3); COPADM (1); COPADM + Auto-SCT/BEAM (1); COPADM + Allo-SCT/Bu/Cy (1) CEEP/DHAP + Auto-SCT/BEAM (1); RCHOP (4); CHOP (1); Steroids# (1); R-CEEP Allo-SCT/TBI/Cy (1) | 12/16 (75) | 0.42 |
| Macpherson et al112 1999 | 15/39 (38) | CHOP-variant or cyclophosphamide + MTX (6); HDC +/− SCT (3); P (4) | NA | 0.21 |
| Niitsu et al12 2009 | 19/19 (100) | CyclOBEAP (6); CHOP + HD MTX (3); CHOP (4); RCHOP (3), CyclOBEAP + R (3) | 17/19 (89) | 1.50 |
| Snuderl et al14 2010 | 20/20 (100) | R-ICE + MTX/ASCT (1); CHOP (1); RCHOP (3); RCHOP + MTX (6); RCHOP + MTX + ASCT (1); R-EPOCH + MTX (3); CODOX- + MTX/R-IVAC (3); P (1); NK(1) | 10/20** (50) | 0.38 |
| Tomita et al11 2009 | 27/27 (100) | CHOP or CODOX-M/IVAC or HyperCVAD (+ R, n = 14; -R, n = 8)†† | 6/23 (26)†† | 0.50‡‡ |
| Study . | No. of DH/total study size (%) . | Treatment regimen* . | Overall response rate, n/N (%)† . | Median survival, y . |
|---|---|---|---|---|
| Bertrand et al40 2007 | 10/17 (59) | NA | 5/10‡ (50) | < 1§ |
| Johnson et al15 2009 | 54/54 (100) | RCHOP (11/54);HDC+/− SCT‖ (6/54); CHOP (23/54); P (14/54) | NA | HD, 0.26; RCHOP, 1.40; CHOP-like, 0.42; P 0.07 |
| Kanungo et al13 2006 | 14/14 (100) | CT-NOS (11); R¶ (1); CT and BMT (1); CT, BMT, and RT (1) | NA | < 1§ |
| Le Gouill et al10 2007 | 16/16 (100) | CEEP/COPADM + Auto-SCT/BEAM (1); CHOP/IVAM (1); COPADM/CYVE (3); COPADM (1); COPADM + Auto-SCT/BEAM (1); COPADM + Allo-SCT/Bu/Cy (1) CEEP/DHAP + Auto-SCT/BEAM (1); RCHOP (4); CHOP (1); Steroids# (1); R-CEEP Allo-SCT/TBI/Cy (1) | 12/16 (75) | 0.42 |
| Macpherson et al112 1999 | 15/39 (38) | CHOP-variant or cyclophosphamide + MTX (6); HDC +/− SCT (3); P (4) | NA | 0.21 |
| Niitsu et al12 2009 | 19/19 (100) | CyclOBEAP (6); CHOP + HD MTX (3); CHOP (4); RCHOP (3), CyclOBEAP + R (3) | 17/19 (89) | 1.50 |
| Snuderl et al14 2010 | 20/20 (100) | R-ICE + MTX/ASCT (1); CHOP (1); RCHOP (3); RCHOP + MTX (6); RCHOP + MTX + ASCT (1); R-EPOCH + MTX (3); CODOX- + MTX/R-IVAC (3); P (1); NK(1) | 10/20** (50) | 0.38 |
| Tomita et al11 2009 | 27/27 (100) | CHOP or CODOX-M/IVAC or HyperCVAD (+ R, n = 14; -R, n = 8)†† | 6/23 (26)†† | 0.50‡‡ |
NA indicates not available; RCHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; HDC, high-dose chemotherapy; SCT, stem cell transplantation; P, palliative; R, rituximab; CT-NOS, intensive combination chemotherapy, not otherwise specified; BMT, bone marrow transplantation; RT, radiotherapy; CEEP, cyclophosphamide, etoposide, epidoxorubicin, and cisplatin; COPADM, cyclophosphamide, vincristine, prednisone, doxorubicin, and high-dose methotrexate; BEAM, carmustine, etoposide, cytarabine, and melphalan; IVAM, ifosfamide, etoposide, cytarabine, and methotrexate; CYVE, cytarabine and etoposide; Bu, busulfan; Cy, cyclophosphamide; DHAP, dexamethason, high-dose cytarabine, and cisplatin, TBI, total body irradiation; MTX, methotrexate; CyclOBEAP, cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisone; HD, high dosage; R-ICE, rutuximab plus ifosfamide, carboplatin, and etoposide plus rituximab; ASCT, autologous stem cell transplantation; EPOCH, rituximab plus etoposide, doxorubicin, vincristine, prednisone, and cyclophosphamide; CODOX, cyclophosphamide, vincristine, and doxorubicin; IVAC, ifosfamide, etoposide, and high-dose cytarabine; NK, not known; and CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone.
For details about the treatment regimens we refer to the original papers.
Overall response rate (ORR), complete remission (unconfirmed) + partial response.
Dead before treatment, n = 1.
Calculation of median survival is based on data presented in the original paper.
Auto-SCT, n = 3; Allo-SCT, n = 1.
Given for low-grade B-cell lymphoma, NOS.
Steroids as palliative therapy.
Therapy ongoing, n = 1.
Lymphoma-type DH only, n = 23.
Twenty-three DH lymphomas and 4 DH leukemias.